目的探討人參皂甙Rg3(簡(jiǎn)稱Rg3)與化療藥物聯(lián)合應(yīng)用對(duì)人乳腺浸潤(rùn)性導(dǎo)管癌動(dòng)物模型中腫瘤的生長(zhǎng)及微血管密度的影響。方法采用人乳腺浸潤(rùn)性導(dǎo)管癌癌株原位種植于16只雌性裸鼠,隨機(jī)均分成4組: 聯(lián)合用藥組即環(huán)磷酰胺(CTX) 16 mg/(kg·d)+Rg3 10 mg/(kg·d)、Rg3組[10 mg/(kg·d)]、CTX組[16 mg/(kg·d)]及對(duì)照組。自腫瘤接種第5天開(kāi)始,連續(xù)灌胃55 d,脫頸處死,分別檢測(cè)腫瘤的重量,并計(jì)數(shù)腫瘤內(nèi)微血管密度(MVD)。結(jié)果Rg3組和CTX組對(duì)原位種植腫瘤的生長(zhǎng)有明顯的抑制作用,聯(lián)合治療組抑制腫瘤生長(zhǎng)的作用明顯優(yōu)于Rg3組,且MVD也明顯低于CTX組及對(duì)照組。結(jié)論Rg3與CTX聯(lián)合應(yīng)用能抑制人乳腺癌的生長(zhǎng),降低腫瘤內(nèi)的MVD。
引用本文: 陳大富,趙揚(yáng)冰,白紹槐,史宗道,蔣麗麗. 人參皂甙Rg3與化療藥物聯(lián)合應(yīng)用對(duì)裸鼠原位種植人乳腺癌的影響. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(5): 300-302. doi: 復(fù)制
版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | Mochizuki M, Yoo YC, Matsuzawa K, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenosideRb2, 20(R)and 20(S)ginsenosideRg3, of red ginseng \[J\]. Biol Pharm Bull,1995; 18(9)∶1197. |
2. | 高勇,王杰軍,許青,等.人參皂甙Rg3抑制腫瘤新生血管形成機(jī)制研究 \[J\].第二軍醫(yī)大學(xué)學(xué)報(bào),2001; 22(1)∶40. |
3. | 白紹槐,趙揚(yáng)冰,張旋波,等,人乳腺浸潤(rùn)性導(dǎo)管癌裸鼠移植模型的建立 \[J\].華西醫(yī)科大學(xué)學(xué)報(bào),1999; 30(2)∶220. |
4. | Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool \[J\]. J Clin Oncol,1995; 13(3)∶765. |
5. | Gasparini G, Biganzoli E, Bonoldi E, et al. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy \[J\]. Breast Cancer Res Treat, 2001; 65(1)∶71. |
6. | Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents \[J\]. Int J Cancer,1994; 57(6)∶920. |
7. | Kachel DL, Martin WJ 2nd. Cyclophosphamideinduced lung toxicity: mechanism of endothelial cell injury \[J\]. J Pharmacol Exp Ther, 1994; 268(1)∶42. |
8. | Brem H,Gresser I, Grosfeld J, et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis \[J\]. J Pediatr Surg, 1993; 28(10)∶1253. |
- 1. Mochizuki M, Yoo YC, Matsuzawa K, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenosideRb2, 20(R)and 20(S)ginsenosideRg3, of red ginseng \[J\]. Biol Pharm Bull,1995; 18(9)∶1197.
- 2. 高勇,王杰軍,許青,等.人參皂甙Rg3抑制腫瘤新生血管形成機(jī)制研究 \[J\].第二軍醫(yī)大學(xué)學(xué)報(bào),2001; 22(1)∶40.
- 3. 白紹槐,趙揚(yáng)冰,張旋波,等,人乳腺浸潤(rùn)性導(dǎo)管癌裸鼠移植模型的建立 \[J\].華西醫(yī)科大學(xué)學(xué)報(bào),1999; 30(2)∶220.
- 4. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool \[J\]. J Clin Oncol,1995; 13(3)∶765.
- 5. Gasparini G, Biganzoli E, Bonoldi E, et al. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy \[J\]. Breast Cancer Res Treat, 2001; 65(1)∶71.
- 6. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents \[J\]. Int J Cancer,1994; 57(6)∶920.
- 7. Kachel DL, Martin WJ 2nd. Cyclophosphamideinduced lung toxicity: mechanism of endothelial cell injury \[J\]. J Pharmacol Exp Ther, 1994; 268(1)∶42.
- 8. Brem H,Gresser I, Grosfeld J, et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis \[J\]. J Pediatr Surg, 1993; 28(10)∶1253.